Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Year: 2026
Type: article
Abstract: BACKGROUND: The LAURA study in unresectable stage III EGFR-mutated NSCLC without progression during/after chemoradiotherapy demonstrated significantly improved progression-free survival (PFS) with osimertinib versus placebo after definitive chemoradiotherapy. We report patient-reported outcomes (PROs) from LAURA. PATIENTS AND METHODS: Score changes from baseline (mixed model for repeated measures analysis) and time to confirmed deterioration in health-related quality of life (HRQoL), functioning and symptoms per EORTC QLQ-C30/LC13 questionnaires were analyzed. Tolerability was assessed using the PRO-CTCAE v1.0. RESULTS: Baseline EORTC scores were comparable between treatment arms. Risk of confirmed deterioration in key scales was generally not substantially different between arms (HR [95% CI], global health status/QoL 1.14 [0.74-1.78]; physical function 1.06 [0.65-1.71]; fatigue 1.23 [0.85-1.80]; appetite loss 1.00 [0.63-1.58]; dyspnea 1.30 [0.91-1.86]; coughing 1.17 [0.81-1.71]; pain in chest 1.46 [0.95-2.23]). Over 40 weeks, minimal changes from baseline were observed for key functioning/symptoms in both arms. PRO-CTCAE responses indicated similar tolerability of osimertinib versus placebo for symptom frequency and severity, except for loose/watery stools ("never"/"rarely" frequency vs. "never") and dry skin ("mild" severity vs. "none"). CONCLUSIONS: PRO scores were maintained during osimertinib treatment of unresectable stage III EGFR-mutated NSCLC after definitive chemoradiotherapy. Together with significant PFS benefit and expected, manageable safety, the PRO data support osimertinib treatment in this setting. TRIAL REGISTRATION NUMBER: NCT03521154.
Source: European Journal of Cancer
Institutions: Hospital Del Mar, Hospital del Mar Research Institute, Istanbul University-Cerrahpaşa, Istanbul University, Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Shizuoka Cancer Center, Chinese Academy of Sciences, Zhejiang Cancer Hospital, National Cancer Center Hospital East, Rajavithi Hospital, Rangsit University, Chungbuk National University, Chungbuk National University Hospital, Hospital Clínico Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Instituto Nacional de Enfermedades Neoplásicas, AstraZeneca (United Kingdom), AstraZeneca (Canada), AstraZeneca (United States), Emory University, Winship Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,270
Funder: AstraZeneca
OpenAlex ID: W7153725035